Populationwide breast cancer screening programs have been established in many countries to reduce breast cancer mortality through early detection and treatment. These programs offer routine mammographic screening to women at average risk starting at age 40 to 50 years with frequency of 1 to 3 years and enhanced screening starting at earlier ages to women at elevated risk owing to family history or genetic susceptibility from high-penetrance genetic mutations (eg, in BRCA1/2 or TP53).1 Screening guidelines recommend different approaches to identify women at elevated risk, including the use of risk prediction models with pedigree-level family history information and genetic testing.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Gierach GL, Choudhury PP, García-Closas M. Toward Risk-Stratified Breast Cancer Screening: Considerations for Changes in Screening Guidelines. JAMA Oncol. 2020;6(1):31–33. doi:10.1001/jamaoncol.2019.3820
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: